2020 Commercially Supported Symposia

The following Commercially Supported Symposia (CSS) held during the AAPM 36th Annual Meeting & Preconferences held February 26-March 1, 2020, offered meeting attendees an opportunity to expand their pain management knowledge and gain insight into the important topics and issues facing today's pain specialists.

A Fresh Look at Atypical Opioids as Frontline Analgesics: Science NOT Misconception (CME)

Opioid analgesics are an important part of our therapeutic armamentarium, but can also have serious consequences. As the pendulum swings from liberal opioid prescribing to a more measured approach, clinicians must ensure it does not swing too far. All opioids are not the same and they vary in their potential for respiratory depression, the major cause of overdose death. Three atypical opioids—buprenorphine, tapentadol, and tramadol—are currently available. Unlike conventional opioids that primarily rely on mu-opioid receptor agonism for analgesia and adverse effects, atypical opioids have additional mechanisms of action that increase the separation between desired therapeutic and unwanted effects. In particular, several groups have identified buprenorphine as a preferred opioid for chronic pain because it has a ceiling to respiratory depression. However, buprenorphine’s complex pharmacology and development history, which includes treatment of opioid use disorder, have led to longstanding misconceptions that buprenorphine is a weaker older drug with limited utility. The faculty will address misconceptions about the pharmacology, analgesic efficacy, and safety of buprenorphine, and provide recommendations on the appropriate use of buprenorphine for chronic pain, including conversion strategies for switching from conventional opioids to buprenorphine.

Educational Objectives

After completing this activity, participants should be better able to:

  • Describe the pharmacologic and safety differences between conventional and atypical opioids.
  • Identify appropriate patients who would benefit from buprenorphine as a first-line opioid analgesic.
  • Describe a strategy to transition opioid therapy from full mu-opioid analgesics to buprenorphine when appropriate.

Supported by an educational grant from BioDelivery Sciences International, Inc.

Emerging Trends in Migraine Diagnosis and Treatment (Non-CME)

This presentation will discuss migraine diagnosis, classification, and treatment as well as migraine-associated patient burden.

Educational Objectives

After attending this symposium, participants should be better able to:

  • Explore the underlying biology that establishes migraine as a neurological disease
  • Understand the impact of migraine on patients’ daily lives
  • Understand how to diagnose and classify migraine

Activity sponsored by Novartis

A Common Sense Approach to Lawsuit Prevention, Tax Reduction, and License Protection (Non-CME)

Legally Mine is an asset protection and tax strategy group. The mission of Legally Mine is to empower members of the healthcare community with the knowledge and tools to protect their assets from lawsuits, build professional license safeguards into their legal structures and legitimately reduce their tax liability.

Educational Objectives

After attending this symposium, participants should be better able to:

  • Keep their name and license off of the NPDB. 
  • Eliminate costly legal fees associated with lawsuits. 
  • Protect their earning power.
  • Utilize proven tax strategies.

Activity Sponsored by Legally Mine

AJOVY® (fremanezumab-vfrm) Injection: An anti-CGRP for the Preventive Treatment of Migraine in Adults (Non-CME)

During this presentation, faculty will provide an overview of AJOVY® (fremanezumab-vfrm) injection as a preventive treatment of migraines in adults. The presentation will begin with a discussion of the migraine disease state, including migraine pathophysiology. This will be followed by a review of the efficacy and safety of AJOVY. Additionally, participants will have the opportunity to ask questions of the faculty.

Educational Objectives

After attending this symposium, participants should be better able to:

  • Provide a review of migraine impact, diagnosis, and treatment guidelines
  • Review recent information on migraine pathophysiology and the role of CGRP in ¬migraine
  • Discuss clinical trial study design and background on AJOVY as an anti-CGRP for the preventive treatment of migraine in adults
  • Review the efficacy, safety, and dosing/ administration of AJOVY in clinical trials

Important Safety Information

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. If a hypersensitivity reaction occurs, consider discontinuing AJOVY and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (5% and greater than placebo) were injection site reactions.

Activity sponsored by Teva Pharmaceuticals

Opioid-Induced Respiratory Depression—latest thinking and potential ways to reduce risk (Non-CME)

Over 100 Americans die every day due to OIRD, yet it is not well understood by patients and some Physicians. This Symposium will take participants through the latest thinking and science, and define who is at risk in each segment of the population, from those with legitimate prescriptions to those using Opioids illicitly. It will cover issues of concomitant medications and how they impact the risk profile and will guide participants through a system to mitigate risk in a highly vulnerable population. Dr. Cheatle will provide real-world experience of dealing with patients who are vulnerable, and Dr. Germanovich will give data from a recent study on the novel device. New classes of analgesics, with lower potential for OIRD, will be discussed, and practical guidance on using Opioids of all types will be given.

Educational Objectives

After attending this symposium, participants should be better able to:

  • Understand the latest understanding of, and risks from, OIRD.
  • Understand who is at risk and how Physicians can minimize the issue.
  • Learn about the latest thinking around how to prevent OIRD in the future.
  • Learn about a potential new device to warn of, and potentially prevent, OIRD.

Activity sponsored by Masimo

AAPM member benefits include discounts on educational courses, products, and the Annual Meeting.

Learn More